WALTHAM, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will make a corporate presentation at the 2010 BIO CEO & Investor Conference...
WALTHAM, Mass. and MADRID, Jan. 19 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) and LABEC Pharma, S.L. announced today that LABEC Pharma has met European regulatory...
Test Available Under Inherent Health(TM) Brand Promotes Early Action for Fracture Prevention with Recommendations for Improving Bone Health WALTHAM, Mass., Dec. 17 /PRNewswire-FirstCall/...
WALTHAM, Mass., Dec. 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it has received approval by the State of New York's Department of Health for the...
New Study Published in Annals of Rheumatic Diseases Suggests IL-1 Biology Plays Central Role in Development of Severe Knee Osteoarthritis WALTHAM, Mass. and NEW YORK, Dec. 2...
WALTHAM, Mass., Nov. 12 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) today announced financial and operational results for the third quarter ended September 30...
WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will host a conference call and webcast on Thursday, November 12, 2009, at...
WALTHAM, Mass. and ADA, Mich., Oct. 29 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it has entered into an agreement with Amway Global. With this...
WALTHAM, Mass., Oct. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at...
Subjects on Diets Appropriate for their Genotype Achieved Statistically significant Average Weight Loss of 6.2% of Body Weight at one year Compared to Individuals not on a Diet Matched to Genotype...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales